Free Trial

Liquidia Q3 2023 Earnings Report

Liquidia logo
$12.90 -1.23 (-8.70%)
As of 04/4/2025 04:00 PM Eastern

Liquidia EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Liquidia Revenue Results

Actual Revenue
$3.68 million
Expected Revenue
$4.55 million
Beat/Miss
Missed by -$870.00 thousand
YoY Revenue Growth
N/A

Liquidia Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Liquidia Earnings Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA
See More Liquidia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Liquidia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liquidia and other key companies, straight to your email.

About Liquidia

Liquidia (NASDAQ:LQDA), a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

View Liquidia Profile

More Earnings Resources from MarketBeat